Paratek Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Paratek Pharmaceuticals

14/03/2022 13:31

* Paratek Pharmaceuticals Inc  PRTK.OQ  reported a quarterly
adjusted loss of 66 cents​​ per share for the quarter ended in
December. The mean expectation of four analysts for the quarter
was for a loss of 41 cents per share.
    * Revenue rose 98.5% to $31.80 million from a year ago; 
analysts
expected $35.34 million. 
    * Paratek Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 66 cents​.
    * The mean earnings estimate of analysts had fallen by
about 20.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Paratek Pharmaceuticals Inc shares had fallen by 22.5%
this
quarter.
    * The company reported a quarterly loss of $32.25 million.
    * Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $21.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated March 14 at 01:31 p.m.  ​All
figures in US dollars unless otherwise stated